The $2.4B Oral Macrocycle and Bispecific Surge: Why Big Pharma Is Buying Platform Engines Over Single Assets
Dr. Dereck Mush, MD, MBA
Orbis Medicines
Generative chemistry platform for orally bioavailable macrocyclic peptide drugs.
What they do
Orbis Medicines applies its nGen chemistry platform to synthesize orally bioavailable macrocycles aimed at intracellular protein-protein interactions. Led by CEO Morten Graugaard, it entered a multi-target drug discovery collaboration with Novo Nordisk worth up to 1.4 billion US dollars in September 2026.
The record
- Vertical
- Biotech & Pharma
- Sub-segment
- Oral macrocyclic peptides
- Product type
- Platform software
- Stage
- Series A
- Headquarters
- Copenhagen, Denmark
- Region
- Europe
- Founded
- Not disclosed
- Total funding
- $90M raised
Notable investors: Novo Holdings.
Also in Biotech & Pharma
Related on The Signal
Dr. Dereck Mush, MD, MBA
Expanding the Kinase Perimeter: Oral BTK Inhibition in Mechanical and Inducible Autoimmunity
Dr. Dereck Mush, MD, MBA
An oral GLP-1 pill enters Phase 3, and the obesity race gets a new lane
Dr. Dereck Mush, MD, MBA
The Oral Transition in Rare Disease Crisis Management: Deucrictibant, Bradykinin B2 Receptors, and the Next Phase of Acute HAE Care
Dr. Dereck Mush, MD, MBA